Approved medicines Human trials in product label Metabolic health
Also discussed as: Symlin, SymlinPen
What it is and how it works
Pramlintide is an amylin analogue. Its actions include slowing gastric emptying and suppressing meal-related glucagon secretion. The label places it in the context of insulin-treated diabetes, where glucose effects and hypoglycemia risk must be considered together.
Source for the mechanism context →A closer look at the cited evidence
Human trials in product label
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- DailyMed — Symlin clinical studies and mechanism
- Design
- Controlled studies summarized in the prescribing information.
- Who or what was studied
- Selected people with type 1 or type 2 diabetes using mealtime insulin.
- What was observed
- Studies assessed glycemic outcomes when pramlintide was added to the diabetes treatment context.
- Limits of interpretation
- An adjunctive diabetes indication does not establish a stand-alone weight-loss or wellness use. The insulin-related safety context is essential.
What the evidence means
The cited label describes studies in people with diabetes using mealtime insulin.
Approval and regulatory context
Symlin is approved as an adjunct in selected people with type 1 or type 2 diabetes using mealtime insulin. This is not a general wellness indication.
Safety and uncertainty
Its boxed warning concerns severe hypoglycemia when used with insulin. The label also addresses gastroparesis and hypoglycemia unawareness.
What remains uncertain
A metabolic pathway can be useful in one medical setting and create hazards in another. This profile cannot determine whether the specific label criteria, risks, or monitoring needs apply to an individual.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.